Almaden Genomics

What Almaden Genomics does

Almaden Genomics, LLC operates a single cloud-based product, g.nome, that targets the omics data analysis workflow. The platform is designed to let bioinformaticians, biologists, and data scientists build, run, and visualize bioinformatics pipelines through a visual drag-and-drop interface drawing on a curated toolkit library, with the company claiming it reduces pipeline development from months to minutes and supports data formats ranging from genomic FASTQs to large-scale HDF5s. The platform is delivered as cloud-native SaaS with HIPAA Ready with Attestation, end-to-end encryption (DIME/DARE), AES-256 at-rest encryption, role-based access control, and periodic third-party penetration and vulnerability testing.

The company is incorporated in Texas, USA, headquartered in Dallas, and operates as a portfolio company of Catalyze Partners. Go-to-market is described as a hybrid of product-led growth via the cloud SaaS platform and direct enterprise sales, with contact handled through the company website and a published phone number; pricing is not publicly disclosed and is quoted on a custom annual subscription basis.

The horizontal segmentation spans academic, pharmaceutical, and clinical laboratory buyers, but the company provides no named customers, case studies, funding history, M&A activity, or disclosed revenue. Strategic signaling to date is limited to the g.nome product launch, the Catalyze Partners portfolio relationship, and the HIPAA security posture, all of which position the company for sales into clinical and healthcare-adjacent bioinformatics use cases.

Name

Almaden Genomics

Legal name

Almaden Genomics, LLC

Website

https://almaden.io

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Almaden Genomics operates g.nome, a cloud-based, no-code bioinformatics platform for omics data analysis. It serves bioinformaticians, biologists, and data scientists at academic, pharma, and clinical organizations via custom-priced annual SaaS subscriptions.

Ownership category

akta.pro rank

Product category

Bioinformatics Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518210), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)

Keywords

• Bioinformatics platform
• Omics data analysis
• Genomic data workflows
• Cloud bioinformatics software
• No-code pipeline builder

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Cloud Platform Subscription: SaaS subscription model for the g.nome platform providing cloud-based bioinformatics analysis capabilities. Users access the platform on a subscription basis for workflow creation, computation, and visualization.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Almaden Genomics provides g.nome®, a cloud-native bioinformatics platform that enables users to build, run, and visualize omics data analysis workflows through a visual drag-and-drop interface. The platform removes the need for specialized infrastructure or coding expertise, supporting data types ranging from genomic FASTQs to large-scale HDF5s. It is delivered as a SaaS subscription and targets bioinformaticians, biologists, and data scientists in research and clinical organizations.

Product overview

Almaden Genomics offers a single unified product called g.nome®, a cloud-based bioinformatics platform designed for omics research. The platform provides end-to-end data analysis capabilities, enabling bioinformaticians, biologists, and data scientists to build, run, and visualize workflows through a visual drag-and-drop interface with a curated toolkit library. It supports various data types including genomic FASTQs and large-scale HDF5s, transforming complex biological data into actionable insights in a collaborative cloud environment.

Differentiator

Problem solved

Functional benefit

Brands

• g.nome: Cloud-based bioinformatics platform for omics research that enables workflow creation, computation, and visualization for bioinformaticians, biologists, and data scientists.

Products and services

• g.nome® Cloud-based bioinformatics platform that provides end-to-end omics data analysis through a visual drag-and-drop workflow builder, allowing bioinformaticians, biologists, and data scientists to assemble toolkits from a curated library, run computations, and visualize results in a unified environment without writing code. Supports diverse data formats including genomic FASTQs and large-scale HDF5s, and is delivered as a HIPAA-ready SaaS subscription.

Quantifiable outcome

• Pipeline development time reduced from months to minutes

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Illumina (BaseSpace Sequence Hub): Largest sequencing instrument vendor with an integrated cloud analysis platform. Competes in cloud bioinformatics as part of a much broader sequencing hardware and reagents franchise, with strong distribution leverage into the same customer base.

Direct peers

• Velsera (formerly Seven Bridges): Genomics informatics platform offering cloud-based analysis pipelines for pharma, clinical, and research customers. Direct competitor in cloud bioinformatics with comparable workflow tooling and customer segments.
• Benchling: Cloud platform for life sciences R&D spanning molecular biology, genomics, and process development. Competes for the same biologist and data scientist personas with a broader lab-focused offering, including workflow and notebook tools.
• Partek (Illumina): Genomics and multi-omics analysis software (now part of Illumina) with visual workflows for biologists and bioinformaticians. Closely comparable feature set to g.nome, especially the visual/no-code workflow builder.
• Genedata: Enterprise software platform for biopharma R&D with deep bioinformatics, screening, and omics analysis capabilities. Competes for the same biopharma customer base with more mature enterprise tooling.
• DNAnexus: Cloud-based platform for genomic and biomedical data analysis and management. Direct competitor serving pharma, clinical labs, and researchers with scalable bioinformatics workflows — same customer base and SaaS delivery model as Almaden's g.nome.

Emerging players

• Lifebit Biotech: Cloud genomics platform with federated and AI-driven analysis for pharma and population genomics. Overlaps with Almaden's persona-targeting strategy and cloud-native architecture, focused on translational and clinical genomics.
• BC Platforms: Genomics and clinical data platform providing bioinformatics, data management, and analytics for pharma and healthcare. Comparable in customer segments and emphasis on clinical/research data integration.
• Form Bio: Cloud bioinformatics platform for life sciences R&D built on nextflow-style workflows. Comparable horizontal SaaS play with a strong focus on reproducibility and collaboration in genomics workflows.

Others

• Galaxy Project: Open-source web-based platform for accessible genomic data analysis with a strong bioinformatics user community. Indirect competitor because it is free and open source, but it shapes buyer expectations for no-code workflow tools that Almaden must compete against.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/AlmadenGenomics
• LinkedInlinkedin.com/company/almaden-genomics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Almaden Genomics